Promising early results from The University of Oxford, in collaboration with AstraZeneca plc, Phase III trials that show its candidate vaccine, ChAdOx1 nCoV-2019, is effective at preventing COVID-19 (SARS-CoV-2) and offers a high level of protection.
Professor Andrew Pollard, Director of the Oxford Vaccine Group and Chief Investigator of the Oxford Vaccine Trial, said:
‘These findings show that we have an effective vaccine that will save many lives. Excitingly, we’ve found that one of our dosing regimens may be around 90% effective and if this dosing regimen is used, more people could be vaccinated with planned vaccine supply. Today’s announcement is only possible thanks to the many volunteers in our trial, and the hard working and talented team of researchers based around the world.’
Our vaccine work is progressing quickly. To ensure you have the latest information or to find out more about the trial, please visit the Oxford COVID-19 vaccine web hub or visit the COVID-19 trial website.
Dr Becca Smith, Deputy Director Research & Innovation
“This is a huge boost in the fight against COVID, this is a really usable vaccine , being safe and easy to store/transport. We entered 643 participants here and the work that all teams have done to support this has been phenomenal. There have been lots of patient visits, frantic last minute changes/amendments and some very long weeks to fit it all in. I cannot thank you enough for the work you have done. For those not working directly on the trial the work you have been doing has enabled your colleagues to work on the vaccine trial and so the thanks is for you equally, without you we couldn’t have done it, a real team effort!